Preeclampsia Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

The preeclampsia market was valued at USD 782.97 Million in 2025 and is expected to grow at a CAGR of 8.10%, reaching USD 1706.09 Million by 2035. Market growth is driven by rising maternal health awareness and innovations in early detection and treatment options.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the Preeclampsia Market

United States: The global preeclampsia market, which encompasses diagnostics, therapeutics, and management products for the pregnancy complication affecting 2 to 8% of all pregnancies worldwide, is valued at approximately USD 1.8 billion in 2025. The U.S. is the largest market for preeclampsia diagnostics and management products. The Iran war's primary near-term impact is through pharmaceutical raw material cost inflation, as magnesium sulfate, the primary first-line treatment for severe preeclampsia and eclampsia prevention, and antihypertensive medications including labetalol and hydralazine are manufactured using chemical synthesis processes with petroleum-derived reagents. Drug packaging costs are also rising with general petrochemical price inflation.

Iran: The conflict is creating a humanitarian crisis in maternal healthcare across Iran and conflict-affected territories. WHO and international medical organizations have identified at least 13 Iranian health facilities as conflict-damaged, and the disruption to obstetric and maternal care is severe. Preeclampsia requires specialist obstetric monitoring, blood pressure management, and emergency delivery capability; all of these services require continuous power supply, functioning operating theatres, and uninterrupted pharmaceutical supply chains, all of which have been severely compromised in conflict-affected Iranian cities. The health consequences for pregnant women in conflict zones unable to receive adequate preeclampsia management are life-threatening for both mother and child.

Israel: Israel's maternal healthcare system, including prenatal monitoring and obstetric emergency services, continues to operate but faces significant stress from the emergency healthcare environment. Israeli hospitals have moved some operations underground, which complicates the provision of labour and delivery services for conditions requiring specialist obstetric intervention such as preeclampsia. The call-up of 70,000 military reservists has reduced the civilian medical workforce available for obstetric and maternal services. Emergency deployment of field hospitals with maternal care capabilities has been undertaken to maintain coverage.

Key Takeaways

Government

• WHO, UNFPA, and international humanitarian organizations should prioritize the delivery of magnesium sulfate and antihypertensive medications as essential maternal medicines to conflict-affected Iranian communities, recognising that preeclampsia management gaps will result in maternal and fetal deaths.
• The U.S. FDA and pharmaceutical regulators should monitor the supply chain for magnesium sulfate and key preeclampsia antihypertensives, ensuring that petrochemical-linked manufacturing cost increases do not constrain global supply of these essential maternal medicines.
• Israel's Ministry of Health should establish mobile obstetric units with preeclampsia management capability to provide continuity of maternal care to displaced populations and communities unable to access hospital-based prenatal services.

Market

• The preeclampsia market's humanitarian and essential medicine character provides strong insulation from commercial demand disruption, as preeclampsia management is a life-saving clinical requirement rather than a discretionary healthcare purchase.
• Pharmaceutical manufacturers of magnesium sulfate and antihypertensive medications for obstetric use may face modest raw material cost inflation from petroleum-derived chemical manufacturing inputs, but the essential medicine status limits any ability to defer treatment.
• The conflict is amplifying advocacy for global preeclampsia diagnostic and monitoring tool investment, as the inability to perform routine blood pressure monitoring and urine protein testing in conflict-disrupted prenatal care settings is creating undetected preeclampsia cases.

Procurement

• Hospital pharmacy teams should build emergency reserves of magnesium sulfate injection and key antihypertensives including labetalol for obstetric use, given rising raw material costs and the critical nature of these medications for preeclampsia management.
• International humanitarian procurement agencies should advance orders for rapid preeclampsia diagnostic kits and blood pressure monitoring equipment for deployment to conflict-affected maternal care facilities in and around the conflict zone.
• Maternal health programme procurement coordinators should ensure that preeclampsia management protocols and supplies are included in all emergency humanitarian medical kits being deployed to conflict-affected regions.